Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Colo. , May 24, 2013  Heska Corporation (NASDAQ: ... diagnostic and specialty products, announced today that Dr. ... officer, and Jason Napolitano , executive vice ... Annual Marcum MicroCap Conference, which is being held May 30, ... the Grand Hyatt Hotel. The Company,s presentation ...
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 of the ... Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced ... Background On 2 May 2013, Echo ... entire of the issued and to be issued share capital ... On 20 May 2013, Royalty Pharma announced the terms ...
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... Study Comparing Leading Hepatitis C Therapies Provides ... Insights to Help Guide Clinical Practice, MILAN, Italy, ... first large, randomized, clinical study comparing the,leading therapies for ... Meeting of the European Association for the Study of ...
... of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -, - Safety and ... ... presentation available on Pharmasset website -, - Conference call scheduled for Friday, April 25, 2008 at ... and 7:00 PM CEST (Milan) -, ...
Cached Medicine Technology:Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6
(Date:5/25/2013)... The report “Global Food Encapsulation ... Applications, Ingredients, Shell Materials, Packaging, & Geography: Trends ... encapsulation market with analysis and forecasting of the ... the driving and restraining factors for the global ... and challenges. The market is segmented and revenue ...
(Date:5/25/2013)... Providing patients with their best weight loss is ... management professionals. But, aside from educating patients on how to ... hCG diets also provide patients, who have gained weight ... more control over their lives by achieving their best weight ... factors of weight gain derived from earlier abuse, Diet Doc's ...
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Pradaxa ... suffered serious, life-threatening episodes of internal bleeding while using the ... in U.S. District Court, Southern District of Illinois, Bernstein Liebhard ... website, 818 Pradaxa side effect claims had been ... That’s up from 705 claims reported by the Court on ...
(Date:5/25/2013)... 2013 On May 25, Voices Against ... and advocacy, comments on a new study by the ... cold atmospheric plasma into brain cancer treatment may help ... a Science Daily article, physicists from the ... physicians demonstrated the “synergistic effect of cold atmospheric plasma ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
Breaking Medicine News(10 mins):Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2
... at about 15 months of age to prevent heart disease ... bmj.com today. , High cholesterol which runs ... two in every 1000 people and causes very high levels ... blood. It carries a high risk of death from coronary ...
... expand options, reduce costs for ECC training, ... Heart,Association research has supported education and training programs ... lives each year.,Now, healthcare providers have more ways ... as the organization introduces a,significantly expanded eLearning program. ...
... Hospital Group to Automate and Connect 165 ... Physicians Across 36 Medical Groups, ... the leading provider of clinical software, connectivity and,information solutions that ... Health System (WPAHS) has selected,Allscripts as its Electronic Health Record ...
... to Make a Blood Donation to Honor Blood ... Collectors and Support Their Communities, LAKE ... of September 16-22, 2007, blood collection centers across the,United States ... and Fenwal, Inc. This celebratory week recognizes the important,service blood ...
... requires lifelong dependence on insulin injections, researchers say , ... insulin-linked gene can cause permanent neonatal diabetes, say American ... mutations in 21 people from 16 families. , Permanent ... affects infants and leads to lifelong dependence on insulin ...
... Saturday,September 15 will mark the first national "Short ... advocacy group, will be holding special,events in several ... City and,Washington, DC, musicians with psoriasis will headline ... have a,cookout; and across the country, people with ...
Cached Medicine News:Health News:Experts propose cholesterol tests at 15 months of age 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 3Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 4Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 2Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 3Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 4Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 2Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 3Health News:Gene Mutations May Cause Rare Neonatal Diabetes 2Health News:Psoriasis Cure Now Rolls Out First National 'Short Sleeve Day' Saturday 2
... clip appliers in 10mm and 5mm sizes. ... precise clip placement., ,The LIGACLIP ERCA ... sterile, single patient use instrument designed to ... Surgical Trocars. The instrument delivers 20 titanium ...
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... laboratories to work more efficiently has ... for innovative solutions. With the COBAS ... on-board measurement technologies, robotic handling of ... This supports the very broad menu ...
... are titanium anchors that come in several ... are simple to use and convenient for ... sizes and styles are available: 3.0mm Single ... Sutures, 5.0mm Double Eyelet 2 Sutures, and ...
Medicine Products: